Plus Therapeutics’ (PSTV) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a report published on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock. A number of other analysts have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their price target on Plus Therapeutics […]
D. Boral Capital reissued their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a report published on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock. A number of other analysts have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their price target on Plus Therapeutics […]
